These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 8158354)

  • 1. The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Erion MD; Ghai RD; Peppard JV; Lappe RW; Worcel M
    J Hypertens Suppl; 1993 Dec; 11(5):S220-1. PubMed ID: 8158354
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
    Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
    J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.
    De Lombaert S; Erion MD; Tan J; Blanchard L; el-Chehabi L; Ghai RD; Sakane Y; Berry C; Trapani AJ
    J Med Chem; 1994 Feb; 37(4):498-511. PubMed ID: 8120868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
    Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
    Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
    Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
    J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.
    MacPherson LJ; Bayburt EK; Capparelli MP; Bohacek RS; Clarke FH; Ghai RD; Sakane Y; Berry CJ; Peppard JV; Trapani AJ
    J Med Chem; 1993 Nov; 36(24):3821-8. PubMed ID: 8254611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs of perzinfotel with improved oral bioavailability.
    Baudy RB; Butera JA; Abou-Gharbia MA; Chen H; Harrison B; Jain U; Magolda R; Sze JY; Brandt MR; Cummons TA; Kowal D; Pangalos MN; Zupan B; Hoffmann M; May M; Mugford C; Kennedy J; Childers WE
    J Med Chem; 2009 Feb; 52(3):771-8. PubMed ID: 19146418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
    J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
    Tunny TJ; Ziesak MD; Armstrong R; Klemm SA; Stowasser M; Finn WL; Gordon RD
    J Hypertens Suppl; 1993 Dec; 11(5):S222-3. PubMed ID: 8158355
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
    French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC
    J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.
    Dang Q; Kasibhatla SR; Jiang T; Fan K; Liu Y; Taplin F; Schulz W; Cashion DK; Reddy KR; van Poelje PD; Fujitaki JM; Potter SC; Erion MD
    J Med Chem; 2008 Jul; 51(14):4331-9. PubMed ID: 18570362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible pegylation prolongs the hypotensive effect of atrial natriuretic peptide.
    Nesher M; Vachutinsky Y; Fridkin G; Schwarz Y; Sasson K; Fridkin M; Shechter Y; Lichtstein D
    Bioconjug Chem; 2008 Jan; 19(1):342-8. PubMed ID: 18069777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon.
    Oefner C; D'Arcy A; Hennig M; Winkler FK; Dale GE
    J Mol Biol; 2000 Feb; 296(2):341-9. PubMed ID: 10669592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
    J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients.
    Johnson AG; Pearce GL; Danoff TM
    J Hum Hypertens; 2006 Jul; 20(7):496-503. PubMed ID: 16543907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.